208 related articles for article (PubMed ID: 18752521)
1. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy.
Querques G; Bocco MC; Soubrane G; Souied EH
Acta Ophthalmol; 2008 Sep; 86(6):694-5. PubMed ID: 18752521
[No Abstract] [Full Text] [Related]
2. Retinal pigment epithelial tear after intravitreal ranibizumab.
Bakri SJ; Kitzmann AS
Am J Ophthalmol; 2007 Mar; 143(3):505-7. PubMed ID: 17317396
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
4. Optical coherence tomography (OCT) features of fibrovascular pigment epithelial detachment (PED).
Phatak S; Subramanyam A; Jayadev C
Retina; 2007; 27(9):1316-8; author reply 1318-9. PubMed ID: 18046248
[No Abstract] [Full Text] [Related]
5. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
6. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
7. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration.
Ahlers C; Golbaz I; Stock G; Fous A; Kolar S; Pruente C; Schmidt-Erfurth U
Ophthalmology; 2008 Aug; 115(8):e39-46. PubMed ID: 18675694
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy.
Mavrakanas N; Mendrinos E; Tabatabay C; Pournaras CJ
Acta Ophthalmol; 2010 Mar; 88(2):e54-5. PubMed ID: 19489761
[No Abstract] [Full Text] [Related]
9. Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration.
Querques G; Souied EH; Soubrane G
Acta Ophthalmol; 2009 Mar; 87(2):235-7. PubMed ID: 19292858
[No Abstract] [Full Text] [Related]
10. Ranibizumab and stroke.
Ueta T; Yanagi Y; Tamaki Y; Yamaguchi T
Ophthalmology; 2010 Sep; 117(9):1860; author reply 1860-1. PubMed ID: 20816253
[No Abstract] [Full Text] [Related]
11. Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration.
Carvounis PE; Kopel AC; Benz MS
Am J Ophthalmol; 2007 Mar; 143(3):504-5. PubMed ID: 17317395
[TBL] [Abstract][Full Text] [Related]
12. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
14. Retinal pigment epithelium tears following intravitreal ranibizumab therapy.
Kiss C; Michels S; Prager F; Geitzenauer W; Schmidt-Erfurth U
Acta Ophthalmol Scand; 2007 Dec; 85(8):902-3. PubMed ID: 17408387
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function.
Kiss CG; Geitzenauer W; Simader C; Gregori G; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2376-83. PubMed ID: 19136707
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
17. Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration.
Konstantinidis L; Ambresin A; Zografos L; Mantel I
Acta Ophthalmol; 2010 Nov; 88(7):736-41. PubMed ID: 19604160
[TBL] [Abstract][Full Text] [Related]
18. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
Keane PA; Chang KT; Liakopoulos S; Jivrajka RV; Walsh AC; Sadda SR
Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab according to need: a treatment for age-related macular degeneration.
Spaide R
Am J Ophthalmol; 2007 Apr; 143(4):679-80. PubMed ID: 17386275
[No Abstract] [Full Text] [Related]
[Next] [New Search]
